Identification of HLA-A*0201/-A*2402-restricted CTL epitopepeptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response

Oncology Reports

Volumn 25, Issue 2, 2011, Pages 469-476

  Kawamoto, Megumi ^a   Tanaka, Fumiaki ^a   Mimori, Koshi ^a   Inoue, Hiroshi ^a   Kamohara, Yukio ^a   Mori, Masaki ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer testis antigen; Cytotoxic T lymphocyte; Immunotherapy

Indexed keywords

AMINO ACID; CANCER TESTIS ANTIGEN; HLA A ANTIGEN; MCAK ANTIGEN; UNCLASSIFIED DRUG; EPITOPE; HLA A*0201 ANTIGEN; HLA A*24:02; HLA-A*0201 ANTIGEN; HLA-A*24:02; KIF2C PROTEIN, HUMAN; KINESIN; PEPTIDE FRAGMENT; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL ISOLATION; COLON CANCER; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN MOTIF; STOMACH CANCER; CELL STRAIN K 562; CELLULAR IMMUNITY; CHEMISTRY; CULTURE TECHNIQUE; CYTOTOXIC T LYMPHOCYTE; ENZYME SPECIFICITY; EPITOPE MAPPING; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASM; TUMOR CELL CULTURE; UPREGULATION;

ANTIGENS, NEOPLASM; CELL CULTURE TECHNIQUES; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; IMMUNITY, CELLULAR; K562 CELLS; KINESIN; NEOPLASMS; PEPTIDE FRAGMENTS; SUBSTRATE SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 78651374344     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1101     Document Type: Article

References (31)

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647, 1991. (Pubitemid 21917508)
2. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P and Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12: 337-365, 1994.
3. Nakamura Y, Tanaka F, Haraguchi N, Mimori K, Matsumoto T, Inoue H, Yanaga K and Mori M: Clinicopathological and biological significance of mitotic centromere-associated kinesin overexpression in human gastric cancer. Br J Cancer 97: 543-549, 2007. (Pubitemid 47258456)
4. Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jäger D, Jäger E, Knuth A and Old LJ: Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 62: 4041-4047, 2002. (Pubitemid 34791072)
5. Gary J: Gorbsky Mitosis: MCAK under the Aura of Aurora B. Curr Biol 14: 346-348, 2004.
6. Brady ST: A novel brain ATPase with properties expected for the fast axonal transport motor. Nature 317: 73-75, 1985.
7. Vale RD, Reese TS and Sheetz MP: Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility. Cell 42: 39-50, 1985.
8. Hirokawa N, Pfister KK, Yorifuji H, Wagner MC, Brady ST and Bloom GS: Submolecular domains of bovine brain kinesin identified by electron microscopy and monoclonal antibody decoration. Cell 56: 867-878, 1989. (Pubitemid 19082522)
9. Endow SA: Kinesin motors as molecular machines. Bioessays 25: 1212-1219, 2003.
10. Wittmann T, Hyman A and Desai A: The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 3: 28-34, 2001. (Pubitemid 32114823)
11. Mori M, Barnard GF, Staniunas RJ, Jessup JM, Steele GD Jr and Chen LB: Prothymosin-α mRNA expression correlates with that of c-myc in human colon cancer. Oncogene 8: 2821-2826, 1993. (Pubitemid 23279111)
12. Shimo A, Tanikawa C, Nishidate T, Meng-Lay L, Matsuda K, Park JH, Ueki T, Ohta T, Hirata K, Fukuda M, Nakamura Y and Katagiri T: Involvement of kinesin family member 2C/ mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci 99: 62-70, 2008. (Pubitemid 350239032)
13. Shimo A, Nishidate T, Ohta T, Fukuda M, Nakamura Y and Katagiri T: Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci 98: 174-181, 2007. (Pubitemid 44941869)
14. Mori M, Mimori K, Yoshikawa Y, Tanaka F and Sugimachi K: Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery 131: S39-S47, 2002. (Pubitemid 34118615)
15. Ogawa K, Utsunomiya T, Mimori K, Tanaka F and Mori M: Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res 11: 2889-2893, 2005. (Pubitemid 40525189)
16. Tanaka F, Fujie T, Go H, Mori M, and Akiyoshi T. Efficient induction of antitumor cytotoxic T lymphocytes from a healthy donor using HLA-A2-restricted MAGE-3 peptide in vitro. Cancer Immunol Immunother 44: 21-26, 1997. (Pubitemid 27135307)
17. Tanaka F, Fujie T, Tahara K, Mori M and Akiyoshi T: Induction of antitumor cytotoxic T lymphocytes with a MAGE- 3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 57: 4465-4468, 1997. (Pubitemid 27441045)
18. Lan W, Zhang X, Kline-Smith SL, et al: Aurora B phosphorylates centromeric MCAK and regulates its localization and microtubule depolymerization activity. Curr Biol 14: 273-286, 2004. (Pubitemid 38300205)
19. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H and Freedman SJ: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109: 500-502, 2007. (Pubitemid 46105945)
20. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K and Mori M: Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 85: 713-720, 2001. (Pubitemid 32929470)
21. Knowlton AL, Lan W and Stukenberg PT: Aurora B is enriched at merotelic attachment sites, where it regulates MCAK. Curr Biol 16: 1705-1710, 2006. (Pubitemid 44691788)
22. Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJ and Schrier PI: Induction and chara cterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int J Cancer 4: 389-396, 1995.
23. Okano F, Storkus WJ, Chambers WH, Pollack IF and Okada H: Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 8: 2851-2855, 2002.
24. Plebanski M, Allsopp CE, Aido M, Reyburn H and Hill AV: Induction of peptide-specific primary cytotoxic T lymphocytes respose from human peripheral blood. Eur J Immunol 25: 1783-1787, 1995.
25. Yamaguchi H, Tanaka F, Ohta M, Inoue H and Mori M: Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response. Clin Cancer Res 10: 890-896, 2004.
26. Yokoe T, Tanaka F, Mimori K, Inoue H, Ohmachi T, Kusunoki M and Mori M: Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis. Cancer Res 68: 1074-1082, 2008. (Pubitemid 351272225)
27. Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jäger D, Jäger E, Knuth A and Old LJ: Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 62: 4041-4047, 2002. (Pubitemid 34791072)
28. Inoue H, Mori M, Honda M, Li J, Shibuta K, Mimori K, Ueo H and Akiyoshi T: The expression of tumor-rejection antigen 'MAGE' genes in human gastric carcinoma. Gastroenterology 109: 1522-1525, 1995.
29. Sahin U, Tureci O and Schmitt H: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92: 11810-11813, 1995. (Pubitemid 26014201)
30. Imanishi T, Akazawa T, Kimura A, Tokunaga K and Gojobori T: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. Oxford Sci Publ 1: 1065-1220, 1992.
31. Wang W, Cassidy J, O'Brien V, Ryan KM and Collie-Duguid E: Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res 64: 8167-8176, 2004. (Pubitemid 39491752)